PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-304.05%
Both yoy net incomes decline, with TRVN at -62.33%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
194.69%
Slight usage while TRVN is negative at -2831.17%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
176.34%
AP growth of 176.34% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-34.25%
Both reduce yoy usage, with TRVN at -2831.17%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
198.30%
Lower 'other non-cash' growth vs. TRVN's 695.49%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
56.08%
Some CFO growth while TRVN is negative at -62.74%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
Some CapEx rise while TRVN is negative at -507.54%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
100.00%
We have mild expansions while TRVN is negative at -507.54%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
42.27%
We repay more while TRVN is negative at -733.33%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.